GEN-MKT-18-7897-A
Nov 18, 2015 | Blogs, Forensic | 0 comments
Facts about Synthetic Cannabinoids and why you need to pay attention to evolving science
Mass spectrometry has proven an excellent tool for testing due to its flexibility to add new analytes as soon as new references become available. Even more compounds have been added to the DEA’s list of controlled substances.
Forensic screening methods for JWH-018 and JWH-073 and their metabolites (two of the main ingredients found in synthetic cannabinoids) using QTRAP technology have already been developed. In 2010, and this validated forensic screening method has been updated to detect JWH-081 and JWH-250 and their metabolites. This is important news when it comes to drug enforcement since the DEA initially announced they would be controlling five synthetic cannabinoids (JWH-018, JWH-073, JWH-200, CP-47, and CP47-C8 homologue). Meanwhile, replacement compounds quickly emerged to include JWH- 081 and JWH-250.
You can read about the results in, “Detecting a New Wave of K2/Spice in Human Urine.” The main takeaways from the article are this:
Download to learn more:
Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.
Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?
As regulatory scrutiny increases and detection requirements tighten, laboratories are facing a new question: How can TFA be measured reliably, sensitively, and at scale?
Posted by
You must be logged in to post a comment.
Share this post with your network